TY - JOUR
T1 - Association between time to colonoscopy after a positive guaiac fecal test result and risk of colorectal cancer and advanced stage disease at diagnosis
AU - Beshara, Amani
AU - Ahoroni, Maya
AU - Comanester, Doron
AU - Vilkin, Alex
AU - Boltin, Doron
AU - Dotan, Iris
AU - Niv, Yaron
AU - Cohen, Arnon D.
AU - Levi, Zohar
N1 - Publisher Copyright:
© 2019 UICC
PY - 2020/3/15
Y1 - 2020/3/15
N2 - We evaluated time to colonoscopy after a positive guaiac-based fecal occult blood test (gFOBT) result and its association with the risk of overall colorectal cancer (CRC) and advanced-stage disease at diagnosis. We conducted a retrospective cohort study (2011–2013) within the Clalit Health Services, Israel. Participants were patients between 50 and 74 years old with a positive gFOBT result who had follow-up colonoscopies within 24 months. The exposure was time to colonoscopy, and the main outcome measure was a risk for overall and advanced CRC (defined as Stages III–IV). Odds ratios (ORs) and 95% confidence intervals (CIs) were adjusted for patient demographics and baseline risk factors. Of the 17,958 patients with positive gFOBT results (median age, 61 years [interquartile range, 56–67 years]; women, 52.2%), there were 685 cases of CRC and 156 cases of an advanced-stage disease diagnosed. The rate of cancer diagnosis at 0–3, 4–6, 7–9, 10–12 and 13–24 months was 3.9%, 2.5%, 3.5%, 4.2% and 7.3%, respectively (p < 0.001). Compared to colonoscopy follow-up within 0–3 months, risks for any CRC and advanced stage disease were higher for a follow-up of 12–24 months: OR, 1.97 (95% CI, 1.51–2.56) and 1.88 (95% CI, 1.43–2.46), respectively. For right-sided cancer (n = 194), an increased risk starts at 10 months, OR, 1.91 (95% CI 1.03–3.56). A result of 3–6 positive fields was significantly associated diagnosis of cancer (OR, 5.52; 95% CI, 4.71–6.46) and advanced stage disease (OR, 8.07; 95% CI, 5.74–11.36). Encouraging an early uptake of colonoscopy and targeting those with 10–24 months delay and a 3–6 positive fields is warranted.
AB - We evaluated time to colonoscopy after a positive guaiac-based fecal occult blood test (gFOBT) result and its association with the risk of overall colorectal cancer (CRC) and advanced-stage disease at diagnosis. We conducted a retrospective cohort study (2011–2013) within the Clalit Health Services, Israel. Participants were patients between 50 and 74 years old with a positive gFOBT result who had follow-up colonoscopies within 24 months. The exposure was time to colonoscopy, and the main outcome measure was a risk for overall and advanced CRC (defined as Stages III–IV). Odds ratios (ORs) and 95% confidence intervals (CIs) were adjusted for patient demographics and baseline risk factors. Of the 17,958 patients with positive gFOBT results (median age, 61 years [interquartile range, 56–67 years]; women, 52.2%), there were 685 cases of CRC and 156 cases of an advanced-stage disease diagnosed. The rate of cancer diagnosis at 0–3, 4–6, 7–9, 10–12 and 13–24 months was 3.9%, 2.5%, 3.5%, 4.2% and 7.3%, respectively (p < 0.001). Compared to colonoscopy follow-up within 0–3 months, risks for any CRC and advanced stage disease were higher for a follow-up of 12–24 months: OR, 1.97 (95% CI, 1.51–2.56) and 1.88 (95% CI, 1.43–2.46), respectively. For right-sided cancer (n = 194), an increased risk starts at 10 months, OR, 1.91 (95% CI 1.03–3.56). A result of 3–6 positive fields was significantly associated diagnosis of cancer (OR, 5.52; 95% CI, 4.71–6.46) and advanced stage disease (OR, 8.07; 95% CI, 5.74–11.36). Encouraging an early uptake of colonoscopy and targeting those with 10–24 months delay and a 3–6 positive fields is warranted.
KW - positive fecal occult blood test
KW - risk of colorectal cancer
KW - time to colonoscopy
UR - http://www.scopus.com/inward/record.url?scp=85068531075&partnerID=8YFLogxK
U2 - 10.1002/ijc.32497
DO - 10.1002/ijc.32497
M3 - Article
AN - SCOPUS:85068531075
SN - 0020-7136
VL - 146
SP - 1532
EP - 1540
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 6
ER -